- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01293331
Study of Febrile Illness for Dengue-Endemic Areas in Latin America
Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Latin America
The purpose of this study is to detect acute febrile episodes and dengue infection in five Latin American countries to assess dengue seroprevalence.
Primary objectives:
- To identify acute febrile episodes among the cohort in order to detect the presence of dengue infection.
- To describe the dengue seroprevalence among the cohort at baseline and at the end of the study.
Study Overview
Status
Conditions
Detailed Description
All participants will make two visits to a study site, an enrollment visit and a termination visit. Additional visits will be made if febrile episodes occur: an acute visit and a convalescent visit. Participants or their parents/guardians will be contacted weekly to monitor the occurrence of febrile episodes and ensure appropriate assessment and care.
No vaccine will be provided or administered in this study
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Campo Grande, Brazil, 79074460
-
Goiania, Brazil, 74675-020
-
Natal-RN, Brazil, 59025-600
-
Vitoria, Brazil, 29040-091
-
-
-
-
-
Acacias Meta, Colombia
-
Aguazul (Casanare), Colombia
-
Bogota, Colombia
-
Calarco (Quindio), Colombia
-
Girardot (Cundinamarca), Colombia
-
La Tebaida (Quindio), Colombia
-
Montenegro (Quindio), Colombia
-
Yopal (Casanare), Colombia
-
-
-
-
-
Municipio de Cd. Mante Tamaulipas, Mexico
-
Quintana Roo., Mexico
-
-
Veracruz Mexico
-
Minatitlan, Veracruz Mexico, Mexico, 96760
-
Veracruz, Veracruz Mexico, Mexico, 91900
-
-
-
-
-
Guayama, Puerto Rico, 00784
-
San Juan, Puerto Rico, 00918
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria :
- Aged 9 to 16 years on the day of inclusion and resident of the site zone
- Participant in good health, based on medical history and physical examination
- Assent form has been signed and dated by the participant (if required by local regulations), and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (and by the participant and/or an independent witness if required by local regulations)
- Participant able to attend all scheduled visits and to comply with all study procedures
Exclusion Criteria :
- Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding enrollment
- Planned participation in another clinical trial during the present study period
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Self-reported seropositivity for Human Immunodeficiency Virus (HIV) infection
- Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
- Current alcohol abuse or drug addiction that may interfere with the participant's ability to comply with study procedures
- Receipt of blood or blood-derived products in the past 3 months
- Receipt of any vaccine in the 4 weeks preceding the day of enrollment except for pandemic influenza vaccination, which may be received at least 2 weeks before enrollment
- Planned receipt of any vaccine in the 4 weeks following enrollment
- Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Study Cohort (Case )
Participants will be examined for fever in dengue endemic regions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identification of acute febrile episodes in the cohort
Time Frame: Up to 18 months after study entry
|
Up to 18 months after study entry
|
Detection of confirmed or probable dengue infection in the cohort
Time Frame: Up to 18 months after study entry
|
Up to 18 months after study entry
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Regional Director, Sanofi Pasteur SA.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CYD35
- U1111-1112-8481 (Other Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fever
-
Meir Medical CenterCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
The Scientific and Technological Research Council...MonitorCROCompleted
-
Tongji HospitalRecruitingHFRS (Hemorrhagic Fever With Renal Syndrome)China
-
U.S. Army Medical Research and Development CommandBausch Health Americas, Inc.WithdrawnCrimean-Congo Hemorrhagic Fever | Lassa FeverGermany
-
Carina Mari ApariciWithdrawnFever of Unknown OriginUnited States
-
University Hospital, GrenobleCompletedFever of Unknown OriginFrance
-
Tongji HospitalUnknownFever of Unknown OriginChina
-
Beijing Friendship HospitalUnknown